LAGging behind no more: PD-1 has a new immunotherapy partner

PD-1 blockade partially reverses T cell exhaustion in cancer patients, but broad responses are still limited. Three studies recently published in Cell illuminate how abrogating LAG-3 and PD-1 synergize to further push effector T cell functionality via distinct molecular mechanisms. PD-1 blockade par...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Immunity (Cambridge, Mass.) Mass.), 2024-10, Vol.57 (10), p.2266-2268
1. Verfasser:	Gunderson, Andrew J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antigens, CD - immunology Antigens, CD - metabolism Humans Immune Checkpoint Inhibitors - pharmacology Immune Checkpoint Inhibitors - therapeutic use Immunotherapy - methods Lymphocyte Activation Gene 3 Protein Neoplasms - immunology Neoplasms - therapy Programmed Cell Death 1 Receptor - antagonists & inhibitors Programmed Cell Death 1 Receptor - immunology T-Lymphocytes - immunology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	PD-1 blockade partially reverses T cell exhaustion in cancer patients, but broad responses are still limited. Three studies recently published in Cell illuminate how abrogating LAG-3 and PD-1 synergize to further push effector T cell functionality via distinct molecular mechanisms. PD-1 blockade partially reverses T cell exhaustion in cancer patients, but broad responses are still limited. Three studies recently published in Cell illuminate how abrogating LAG-3 and PD-1 synergize to further push effector T cell functionality via distinct molecular mechanisms.
ISSN:	1074-7613 1097-4180 1097-4180
DOI:	10.1016/j.immuni.2024.09.010